Ticker: APRE

Aprea Therapeutics (NASDAQ:APRE) stock dropped nearly 20% following early-stage trial data for APR-1051, highlighting mixed outcomes and cautious investor reaction.

Aprea Therapeutics, Inc. (NASDAQ: APRE) Short take - Clinical-stage oncology biotech focused on synthetic lethality (WEE1 inhibitor APR-1051; ATR inhibitor ATRN-119). Management is advancing two Phase‑1 programs and reports limited cash runway: ~ $16.5M on hand, continued quarterly losses and a f...

Aprea Therapeutics, Inc. (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on developing targeted cancer treatments through synthetic lethality mechanisms. For the first quarter of 2025, Aprea continues to face significant challenges in both financial performance and clinical d...